Why the study?
Reductions in Na+-K+-ATPase (NKA) activity occur in heart failure, but NKA α1 mutation or knockdown does not cause spontaneous heart disease, leaving it unknown whether abnormal NKA α1 directly contributes to heart failure pathogenesis.
Does NKA α1 haploinsufficiency exacerbate isoproterenol-induced cardiac dysfunction, and does DRm217 alleviate it in a mouse model?
Does NKA α1 haploinsufficiency exacerbate isoproterenol-induced cardiac dysfunction, and does DRm217 alleviate it in a mouse model?
NKA α1 haploinsufficiency exacerbates isoproterenol-induced cardiac dysfunction via mitochondrial Ca2+ depression and metabolic downregulation, which can be mitigated by DRm217.
NKA α1 loss may accelerate remodeling in stressed mouse hearts; leaves open whether DRm217 offers a viable therapeutic target in human HF.
Reductions in Na+-K+-ATPase (NKA) activity and expression are often observed in the progress of various reason-induced heart failure (HF). However, NKA α1 mutation or knockdown cannot cause spontaneous heart disease. Whether the abnormal NKA α1 directly contributes to HF pathogenesis remains unknown. Here, we challenge NKA α1+/- mice with isoproterenol to evaluate the role of NKA α1 haploinsufficiency in isoproterenol (ISO)-induced cardiac dysfunction. Genetic knockdown of NKA α1 accelerated ISO-induced cardiac cell hypertrophy, heart fibrosis, and dysfunction. Further studies revealed decreased Krebs cycle, fatty acid oxidation, and mitochondrial OXPHOS in the hearts of NKA α1+/- mice challenged with ISO. In ISO-treated conditions, inhibition of NKA elevated cytosolic Na+, further reduced mitochondrial Ca2+ via mNCE, and then finally down-regulated cardiac cell energy metabolism. In addition, a supplement of DRm217 alleviated ISO-induced heart dysfunction, mitigated cardiac remodeling, and improved cytosolic Na+ and Ca2+ elevation and mitochondrial Ca2+ depression in the NKA α1+/- mouse model. The findings suggest that targeting NKA and mitochondria Ca2+ could be a promising strategy in the treatment of heart disease.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: